Research ExplorerPublicationsChallenges with defining response to antitumor agents in ped...

Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group

Standard

Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. / Warren, Katherine E; Poussaint, Tina Y; Vezina, Gilbert; Hargrave, Darren; Packer, Roger J; Goldman, Stewart; Wen, Patrick Y; Pollack, Ian F; Zurakowski, David; Kun, Larry E; Prados, Michael D; Rutkowski, Stefan; Kieran, Mark W.

In: PEDIATR BLOOD CANCER, Vol. 60, No. 9, 01.09.2013, p. 1397-401.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Warren, KE, Poussaint, TY, Vezina, G, Hargrave, D, Packer, RJ, Goldman, S, Wen, PY, Pollack, IF, Zurakowski, D, Kun, LE, Prados, MD, Rutkowski, S & Kieran, MW 2013, 'Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group', PEDIATR BLOOD CANCER, vol. 60, no. 9, pp. 1397-401. https://doi.org/10.1002/pbc.24562

APA

Warren, K. E., Poussaint, T. Y., Vezina, G., Hargrave, D., Packer, R. J., Goldman, S., Wen, P. Y., Pollack, I. F., Zurakowski, D., Kun, L. E., Prados, M. D., Rutkowski, S., & Kieran, M. W. (2013). Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. PEDIATR BLOOD CANCER, 60(9), 1397-401. https://doi.org/10.1002/pbc.24562

Vancouver

Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Goldman S et al. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. PEDIATR BLOOD CANCER. 2013 Sep 1;60(9):1397-401. https://doi.org/10.1002/pbc.24562

Bibtex

@article{5ed5dd2f8aaf433cb5a2f7b4037590fb,
title = "Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group",
abstract = "Criteria for new drug approval include demonstration of efficacy. In neuro-oncology, this is determined radiographically utilizing tumor measurements on MRI scans. Limitations of this method have been identified where drug activity is not reflected in decreased tumor size. The RANO (Response Assessment in Neuro-Oncology) working group was established to address limitations in defining endpoints for clinical trials in adult neuro-oncology and to develop standardized response criteria. RAPNO was subsequently established to address unique issues in pediatric neuro-oncology. The aim of this paper is to delineate response criteria issues in pediatric clinical trials as a basis for subsequent recommendations.",
keywords = "Adolescent, Adult, Antineoplastic Agents, Child, Child, Preschool, Clinical Trials as Topic, Female, Humans, Infant, Infant, Newborn, Male, Neoplasms, Nerve Tissue",
author = "Warren, {Katherine E} and Poussaint, {Tina Y} and Gilbert Vezina and Darren Hargrave and Packer, {Roger J} and Stewart Goldman and Wen, {Patrick Y} and Pollack, {Ian F} and David Zurakowski and Kun, {Larry E} and Prados, {Michael D} and Stefan Rutkowski and Kieran, {Mark W}",
note = "Copyright {\textcopyright} 2013 Wiley Periodicals, Inc.",
year = "2013",
month = sep,
day = "1",
doi = "10.1002/pbc.24562",
language = "English",
volume = "60",
pages = "1397--401",
journal = "PEDIATR BLOOD CANCER",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group

AU - Warren, Katherine E

AU - Poussaint, Tina Y

AU - Vezina, Gilbert

AU - Hargrave, Darren

AU - Packer, Roger J

AU - Goldman, Stewart

AU - Wen, Patrick Y

AU - Pollack, Ian F

AU - Zurakowski, David

AU - Kun, Larry E

AU - Prados, Michael D

AU - Rutkowski, Stefan

AU - Kieran, Mark W

N1 - Copyright © 2013 Wiley Periodicals, Inc.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Criteria for new drug approval include demonstration of efficacy. In neuro-oncology, this is determined radiographically utilizing tumor measurements on MRI scans. Limitations of this method have been identified where drug activity is not reflected in decreased tumor size. The RANO (Response Assessment in Neuro-Oncology) working group was established to address limitations in defining endpoints for clinical trials in adult neuro-oncology and to develop standardized response criteria. RAPNO was subsequently established to address unique issues in pediatric neuro-oncology. The aim of this paper is to delineate response criteria issues in pediatric clinical trials as a basis for subsequent recommendations.

AB - Criteria for new drug approval include demonstration of efficacy. In neuro-oncology, this is determined radiographically utilizing tumor measurements on MRI scans. Limitations of this method have been identified where drug activity is not reflected in decreased tumor size. The RANO (Response Assessment in Neuro-Oncology) working group was established to address limitations in defining endpoints for clinical trials in adult neuro-oncology and to develop standardized response criteria. RAPNO was subsequently established to address unique issues in pediatric neuro-oncology. The aim of this paper is to delineate response criteria issues in pediatric clinical trials as a basis for subsequent recommendations.

KW - Adolescent

KW - Adult

KW - Antineoplastic Agents

KW - Child

KW - Child, Preschool

KW - Clinical Trials as Topic

KW - Female

KW - Humans

KW - Infant

KW - Infant, Newborn

KW - Male

KW - Neoplasms, Nerve Tissue

U2 - 10.1002/pbc.24562

DO - 10.1002/pbc.24562

M3 - SCORING: Journal article

C2 - 23625747

VL - 60

SP - 1397

EP - 1401

JO - PEDIATR BLOOD CANCER

JF - PEDIATR BLOOD CANCER

SN - 1545-5009

IS - 9

ER -